Novavax Inc and its partner Serum Institute of India have applied to the World Health Organisation for an emergency use listing of Novavax's Covid-19 vaccine, the company said.
Novavax has said it would focus on low- and middle-income countries for initial supplies of the vaccine, as the United States and other Western nations have already vaccinated a large part of their populations with other vaccines, according to a Reuters report.
The Novavax shot is a protein-based vaccine, and was shown to be more than 90 per cent effective, including against a variety of concerning variants of the coronavirus in a large, late-stage US-based clinical trial.
